Arbutus Biopharma Corp
Ownership
Ownership Structure
Who owns Arbutus Biopharma Corp (ABUS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 98.2% of the shares are freely tradable; institutional investors hold 71.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Two Seas Capital LP | 12.11 | 18,557,543 | +47.4 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 11.55 | 17,698,305 | -31.6 | 06/30/2026 |
| Whitefort Capital Management, LP. | 10.30 | 15,794,261 | +5.8 | 06/30/2026 |
| BlackRock Inc | 8.98 | 13,766,071 | +6.2 | 06/30/2026 |
| State Street Corp | 5.13 | 7,869,179 | +24.1 | 06/30/2026 |
| Rubric Capital Management LP | 4.91 | 7,532,937 | +13.7 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.57 | 7,010,679 | +4.8 | 06/30/2026 |
| Barclays PLC | 2.75 | 4,207,914 | -2.5 | 06/30/2026 |
| Geode Capital Management, LLC | 2.69 | 4,117,691 | +9.2 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.28 | 5,034,547 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director | 29,880,079 | 119,520,316 $ | Oct 1, 2026 | direct |
| Nguyen Tuan | Chief Financial Officer | 111,882 | 447,528 $ | Oct 1, 2026 | direct |
| Androski Lindsay | President and CEO | 47,682 | 190,728 $ | Oct 1, 2026 | direct |
| Beardsley Robert A | Director | 14,328 | 57,312 $ | Oct 1, 2026 | direct |
| Sawhney Roger | Director | 13,683 | 54,732 $ | Oct 1, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Beardsley Robert A | Director | Other | 17,948 | 5.00 | 89,740 |
| Oct 1, 2026 | Nguyen Tuan | Chief Financial Officer | Other | 48,081 | 5.00 | 240,405 |
| Oct 1, 2026 | Sawhney Roger | Director | Other | 17,142 | 5.00 | 85,710 |
| Oct 1, 2026 | Androski Lindsay | President and CEO | Other | 24,655 | 5.00 | 123,275 |
| Oct 1, 2026 | Roivant Sciences Ltd. | Director | Other | 8,967,383 | 5.00 | 44,836,915 |
| Sep 18, 2026 | Androski Lindsay | President and CEO | Other | 82,527 | 5.07 | 418,412 |
| Sep 18, 2026 | Androski Lindsay | President and CEO | Other | 10,456 | 4.39 | 45,902 |
| Sep 18, 2026 | Androski Lindsay | President and CEO | Other | 116,408 | 3.20 | 372,506 |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | Other | 206,637 | 5.07 | 1,047,650 |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | Other | 27,475 | 4.39 | 120,615 |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | Other | 265,625 | 3.49 | 927,031 |
| Sep 18, 2026 | Sawhney Roger | Director | Other | 100,508 | 5.07 | 509,576 |
| Sep 18, 2026 | Sawhney Roger | Director | Other | 78,800 | 4.24 | 334,112 |
| Sep 18, 2026 | Sawhney Roger | Director | Other | 52,533 | 3.34 | 175,460 |
| Sep 18, 2026 | Beardsley Robert A | Director | Other | 99,057 | 5.07 | 502,219 |
| Sep 18, 2026 | Beardsley Robert A | Director | Other | 78,800 | 4.24 | 334,112 |
| Sep 18, 2026 | Beardsley Robert A | Director | Other | 52,533 | 3.20 | 168,106 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.